鞍重股份(002667.SZ)擬定增募資不超3.43億元 控股股東全額認購
格隆匯3月9日丨鞍重股份(002667.SZ)披露2021年非公開發行A股股票預案,此次非公開發行股票募集資金總額(含發行費用)為不超過約3.43億元,扣除發行費用後的募集資金淨額將全部用於補充公司流動資金。
此次非公開發行股票數量不超過6933.96萬股股票(含此數),且不超過此次發行前總股本的30%。此次非公開發行股票的價格為4.94元/股。
此次發行為面向特定對象的非公開發行,發行對象為公司控股股東上海翎翌科技有限公司(“上海翎翌”)。上海翎翌以現金方式認購公司此次非公開發行的股票。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.